TerrAscend Corp.

TSX:TSND.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.52 -1.61%

-$0.02 today

Market cap
$193.65M
Beta
2.04
P/E (TTM)
-2.5
EPS (TTM)
-$0.26
52W Low $0.33High $2.00

Volume 0.26M

Average 0.31M

TSND.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

TerrAscend Corp.TSX: TSND.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $885K fell 41.5% year over year, ahead of the -55.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 34.3% from the prior quarter. Over 3 fiscal years it compounded at -25.6% a year.

Context

  • Stock-based compensation amounted to 1.9% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -41.5% holds above the trailing-twelve-month pace of -55.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$885K-34.3% QoQ
Last fiscal yearDec 2025
$5.01M-48.4% YoY
LTMMar 2026
$4.38M-55.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.5%——
1 year-48.4%——
3-year CAGR-25.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.01M USD
Year-over-year change
-48.4%
4-year CAGR
-23.9%

Stock-Based Compensation vs competitors

How TSND.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -55.0% is the lowest of 10, against a peer median of +54.8%.
  • Stock-based compensation amounts to 1.7% of revenue for TSND.TO, versus a peer median of 2.4%.
TSND.TO Competitors
Stock-Based Compensation for TSND.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$9.67M USD+143.3%+84.7%—
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$7.29M CAD-36.7%-24.4%2.3%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$7.23M USD+54.8%+18.6%14.1%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$5.06M CAD+220.3%-44.8%1.6%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$4.81M CAD+5.0%+9.4%3.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$4.38M USD-55.0%-25.6%1.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$3.45M CAD-36.6%—1.3%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$1.8M USD+64.7%+62.8%3.5%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.4M USD-30.3%-13.2%2.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$246K USD+228.0%—0.1%
Peer median (excluding TSND.TO) —+54.8%+9.4%2.4%

Competitors are the stored peer set for TSND.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.82M)22.61M(27.63M)(72.67M)(24.49M)
Depreciation & Amortization13.63M23.87M30.64M22.99M17.51M
Deferred Income Tax(1.81M)(46.02M)(18.92M)(8.75M)(532K)
Stock-Based Compensation14.93M12.18M7.71M9.71M5.01M
Change in Working Capital(45.17M)37.81K35.67M28.84M23.24M
Accounts Receivables(4.02M)3.73M(12.5M)(2.95M)1.67M
Inventory(23.19M)881.27K(7M)4.17M6.05M
Accounts Payables3.53M(15.78M)869.2K(5.29M)(4.59M)
Other Working Capital(21.49M)11.2M52.07M32.91M20.11M
Other Non-Cash Items(4.62K)(38.8M)(2.42K)57.84M1.34M
Operating Cash Flow(38.43M)(33.38M)27.47M37.95M22.07M
Capital Expenditures(50.39M)(54.61M)(9.43M)(10.55M)(8.76M)
Acquisitions (Net)(53.55M)19.77M(16.79M)(250K)(8.68M)
Purchases of Investments(62.65M)0000
Sales of Investments00000
Other Investing Activities34.17M7.27M5.44M(2.64M)3.16M
Investing Cash Flow(132.42M)(27.58M)(16.22M)(12.25M)(15.03M)
Debt Repayment(3.67M)54.4K(27.76M)(17.18M)8.36M
Common Stock Issued200.83M23.62M20.82M00
Common Stock Repurchased000(215K)(417.18K)
Dividends Paid00000
Other Financing Activities(14.96M)(19.95M)(5.56M)(7.32M)(3.69M)
Financing Cash Flow182.2M3.72M(12.5M)(24.72M)4.26M
Effect of Forex Changes2.45M(2.9M)(168K)653K(2.11M)
Net Change in Cash20.42M(52.88M)(1.42M)1.64M9.19M
Free Cash Flow(88.82M)(88M)18.04M27.4M13.31M

TerrAscend Corp.

TSX:TSND.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.